Charles Schwab
OTLK icon

Charles Schwab’s Outlook Therapeutics OTLK Stock Holding History

Charles Schwab’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-36,060
Closed -$44K – 3548
2025
Q1 		$44K Buy
36,060
+12
+0% +$21 ﹤0.01% 3415
2024
Q4 		$68.1K Sell
36,048
-15,411
-30% -$63.4K ﹤0.01% 3424
2024
Q3 		$275K Buy
51,459
+18,287
+55% +$134K ﹤0.01% 3302
2024
Q2 		$245K Buy
33,172
+15,442
+87% +$124K ﹤0.01% 3411
2024
Q1 		$212K Sell
17,730
-1
-0% -$8 ﹤0.01% 3230
2023
Q4 		$140K Hold
17,731
– – ﹤0.01% 3319
2023
Q3 		$78.4K Sell
17,731
-3,125
-15% -$69.1K ﹤0.01% 3373
2023
Q2 		$726K Buy
20,856
+242
+1% +$6.6K ﹤0.01% 2885
2023
Q1 		$449K Buy
20,614
+4,151
+25% +$92.9K ﹤0.01% 2984
2022
Q4 		$356K Hold
16,463
– – ﹤0.01% 3077
2022
Q3 		$402K Sell
16,463
-86
-0.5% -$2K ﹤0.01% 3064
2022
Q2 		$338K Buy
16,549
+714
+5% +$20.5K ﹤0.01% 3175
2022
Q1 		$564K Buy
15,835
+4,832
+44% +$151K ﹤0.01% 3066
2021
Q4 		$300K Hold
11,003
– – ﹤0.01% 3285
2021
Q3 		$478K Hold
11,003
– – ﹤0.01% 3163
2021
Q2 		$548K Buy
11,003
+9,281
+539% +$431K ﹤0.01% 3139
2021
Q1 		$78K Buy
+1,722
New +$65.9K ﹤0.01% 3400

Other funds holding OTLK

SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Charles Schwab's OTLK Position: Q2 2025 in Review

Charles Schwab sold out of Outlook Therapeutics (OTLK) in Q2 2025, closing a stake of 36,060 shares — an estimated $44K sold.

Charles Schwab first reported a position in OTLK in Q1 2021 and held it in 17 quarters. The position peaked at $726K in Q2 2023. 66 funds tracked by Wall St. Rank hold OTLK as of Q2 2025.

  • Charles Schwab reported no remaining Outlook Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Charles Schwab sold 36,060 Outlook Therapeutics shares in Q2 2025, an estimated $44K.
  • Charles Schwab first reported a position in Outlook Therapeutics in Q1 2021 and held it in 17 quarters.
  • Charles Schwab's Outlook Therapeutics position peaked at $726K in Q2 2023.
  • 66 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2025.

Based on Charles Schwab's 13F filing for Q2 2025, filed 12 Aug 2025.